-

Dr. Vince Clinical Research Appoints World-Renowned Drug Developer, Clinical Pharmacologist and Neuroscientist Dr. Sheldon Preskorn as Senior VP of Neuroscience

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Dr. Vince Clinical Research (DVCR), a full-service contract research organization (CRO), today announced the appointment of Sheldon Preskorn, M.D., as its Senior Vice President of Neuroscience. Dr. Preskorn is a world-renowned researcher, academic physician, psychiatrist, clinical researcher, neuropsychopharmacologist and medical educator. He has worked with over 140 pharmaceutical, biotech, device and diagnostic companies and has worked on 16 successful new drug applications. His publications include over 500 medical papers, books and book chapters, with over 18,000 citations in medical literature. Further, Dr. Preskorn has served as a consultant to the FDA, EMA and NIH and has lectured in 55 countries and at most medical schools in the U.S. and throughout the world.

Dr. Vince Clinical Research appoints world-renowned drug developer, clinical pharmacologist and neuroscientist Dr. Sheldon Preskorn as senior VP of neuroscience.

Share

Dr. Preskorn stated: “I have been working in drug development research for 40 years and am pleased to continue my work with DVCR. My lifelong goal has been to advance the treatment of patients suffering from neuropsychiatric disorders and believe this collaboration will greatly advance the ability of our clients to bring breakthrough therapies for patients suffering from these serious medical conditions.”

DVCR CEO and Chief Medical Officer, Brad Vince, D.O., stated: “It is a true honor to work alongside such a well-respected and highly experienced clinical pharmacologist. The addition of Dr. Preskorn to DVCR’s leadership team provides our company and our biopharmaceutical clients access to his significant neurological and psychiatric clinical research expertise.”

About Dr. Vince Clinical Research

Dr. Vince Clinical Research (DVCR) is a full-service contract research organization (CRO) specializing in early phase trials in both healthy normal volunteers and patient populations across a wide range of trial designs and therapeutic areas such as neuroscience, substance abuse, pain, cardiometabolic disorders, infectious diseases and many others. CRO services include project management, data management, biostatistics, statistical programming, PK/PD analysis, medical writing, monitoring as well as site feasibility and management for multi-site trials. Additionally, DVCR operates one of the most innovative and technologically advanced clinical pharmacology units in the world with over 90 beds for overnight confinement, a cGMP compliant pharmacy as well as luxurious amenities to support diverse study participant recruitment and retention. By leveraging technology and one of the country’s most experienced leadership teams in early clinical development, DVCR provides Smarter Faster Data® to their biopharmaceutical clients.

Contacts

Zach Bader
Vice President, Business Development
(913) 333-3000
info@drvince.com

Dr. Vince Clinical Research


Release Summary
Dr. Vince Clinical Research (DVCR) today announced the appointment of Sheldon Preskorn, M.D., as its Senior Vice President of Neuroscience.
Release Versions

Contacts

Zach Bader
Vice President, Business Development
(913) 333-3000
info@drvince.com

Social Media Profiles
More News From Dr. Vince Clinical Research

Dr. Vince Clinical Research Announces First Dosing in a Phase II Study in Patients With Depression

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Dr. Vince Clinical Research announced the first dosing in a Phase II multicenter trial of SPN-820 in adults with major depressive disorder (MDD)....

Dr. Vince Clinical Research Launches New Solution for Organ Impairment Studies

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Dr. Vince Clinical Research (DVCR) announced a new solution that will challenge the current landscape for managing organ impairment studies....

Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics’ CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Dr. Vince Clinical Research announces the first dosing in Cingulate Therapeutics’ CTx-1301 Phase III laboratory classroom study....
Back to Newsroom